Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Simple breath change could boost COPD inhaler power

NCT ID NCT05381415

Symptom relief Sponsor: University of Milan Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study looks at whether inhaling a bronchodilator (salbutamol) at a different lung volume helps it work better in people with COPD. 30 participants will inhale the medication either from a low lung volume (as usually done) or from a higher, more relaxed volume. The goal is to see if the higher volume leads to better airflow and more even drug distribution, potentially making inhalers easier to use effectively.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
salbutamol (a bronchodilator) inhaled via a spacer
What this could lead to
If it works, this could simplify how COPD patients take their inhalers, making treatment easier and possibly more effective.
What could go wrong
This is a very small, early study (30 people) that has not started yet. It only tests a single dose of one drug, so results may not apply to other medications or long-term use.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 30 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Dec 2026

An estimate. Start dates often move.

Expected to finish

Dec 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients with COPD diagnosis (VEMS/FVC after bronchodilatation \<0.7) will be enrolled in a stable state of disease, diagnosed from at least 12 months \[GOLD\].

Ages

40 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * age above 40 years old; * history of smoking equal or above 10 PKYs; * VEMS after bronchodilatation ≤ 70%, * medical Necessity to perform a bronchodilatation test. Exclusion Criteria: * history of bronchial asthma or other chronic respiratory diseases such as pulmonary fibrosis; * uncontrolled cardiovascular diseases at the time of the visit; * current pregnancy; * incapacity to execute lung function tests for cognitive impairment, substance abuse or claustrophobia; * known hypersensitivity or intolerance to salbutamol.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for COPD are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

acute lung injury chronic obstructive pulmonary disease COPD, severe early onset Lung Injury

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

COPD Lung injury

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • L. Sacco Hospital

    Milan, 20157, Italy

More trials for these conditions

Other studies related to the condition(s) this trial covers.